William Blair analyst Sami Corwin has maintained their neutral stance on QURE stock, giving a Hold rating on November 6.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Sami Corwin has given his Hold rating due to a combination of factors impacting uniQure’s current position and future prospects. One of the primary reasons is the uncertainty surrounding the regulatory path for AMT-130 after the FDA’s preliminary feedback indicated a disagreement with the use of external natural history control for the BLA submission. This has led to unclear timing for the BLA submission, which is a significant factor in the company’s future growth potential.
Additionally, the company has paused enrollment in the Phase I/II EPISOD1 study of AMT-162 due to a dose-limiting toxicity, which introduces further uncertainty and potential risk. While there are positive developments, such as the announcement of data from AMT-260 and promising results from the AMT-191 trial, the focus remains on the resolution of regulatory challenges and the strategic engagement with stakeholders. These mixed signals contribute to the Hold rating as the company navigates these complexities.
In another report released on November 6, TR | OpenAI – 4o also reiterated a Hold rating on the stock with a $25.00 price target.